Company Overview
- Website
- askbio.com
- Phone
- (919) 561-6210
- Employees
- 506
- Founded in
- 2001
- Industry
- BioTech/Drugs
- NAICS Codes
-
54 - Professional, Scientific, and Technical Services541 - Professional, Scientific, and Technical Services5417 - Scientific Research and Development Services54171 - Research and Development in the Physical, Engineering, and Life Sciences541714 - Research and Development in Biotechnology (except Nanobiotechnology)
- SIC Codes
-
87 - Engineering, Accounting, Research, Management, and Related Services873 - Research, Development, and Testing Services
Financials & Stats
Revenue
$19B
Total Funding Amount
$4M
Recent News & Media
Synthetic promoters enhance gene therapy precision
- Apr 28, 2025
- drugtargetreview.com
U.S. gene therapy market Size to Hit USD 18.50 Billion by 2033
- Feb 26, 2025
- biospace.com
Bayer
- Dec 21, 2024
- contractpharma.com
AB-1002 Demonstrates Improvements for Congestive Heart Failure in First-in-Human Study
- Nov 20, 2023
- pharmacytimes.com
Sharon Hesterlee, PhD
- Jul 26, 2023
- mda.org
Viral Vector Market Size, Share & Analysis Report, 2030
- Mar 13, 2023
- grandviewresearch.com
Who is Asklepios BioPharmaceuticals Inc
Asklepios BioPharmaceutical, Inc. (AskBio), headquartered in Research Triangle Park, North Carolina, is a wholly owned subsidiary of Bayer AG. As a fully integrated gene therapy company, AskBio employs 506 people and has generated $19.4 million in revenue. The company focuses on developing life-saving gene therapies for a range of diseases. AskBio's clinical programs target various conditions, including neuromuscular, central nervous system, cardiovascular, and metabolic diseases. Their therapeutic pipeline includes treatments for congestive heart failure, Huntington's disease, limb-girdle muscular dystrophy, multiple system atrophy, Parkinson's disease, and Pompe disease. AskBio's gene therapy platform features Pro10™, a proprietary cell line manufacturing process, and a vast library of capsids and promoters. The company has developed hundreds of proprietary capsids and promoters, many of which are in pre-clinical and clinical testing. AskBio's commitment to innovation is evident in its pioneering approach to gene therapy development, striving to make these life-changing treatments accessible to those in need. For more information, visit AskBio's website at askbio.com.